Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
Open Access
- 22 September 2023
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (12) , 4748-4764
Abstract
No abstract availableKeywords
Funding Information
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2018324)
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2018ZX09711002-011-016)
- National Science and Technology Major Project
- Chinese Academy of Sciences (XDA12020203, XDA12020228)
- National Natural Science Foundation of China (81573271, 82273948)
This publication has 46 references indexed in Scilit:
- Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase InhibitorsACS Medicinal Chemistry Letters, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- CSF-1R inhibition alters macrophage polarization and blocks glioma progressionNature Medicine, 2013
- Investigation of Macrophage Polarization Using Bone Marrow Derived MacrophagesJournal of Visualized Experiments, 2013
- Comprehensive analysis of kinase inhibitor selectivityNature Biotechnology, 2011
- Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding modeBioorganic & Medicinal Chemistry Letters, 2010
- Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapyBlood, 2010
- Glioma angiogenesisCell Adhesion & Migration, 2009
- Novel anti-angiogenic therapies for malignant gliomasThe Lancet Neurology, 2008
- Novel 2,3-Dihydro-1,4-Benzoxazines as Potent and Orally Bioavailable Inhibitors of Tumor-Driven AngiogenesisJournal of Medicinal Chemistry, 2008